Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You Is Abbott's January Pullback a Good Time to Buy? Reported by Thomas Hughes. Posted: 1/24/2026. 
At a Glance - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback is making the stock look attractively valued. The move — driven more by market angst than by any fundamental weakness — appears to be a knee-jerk overreaction that has returned the shares to a compelling buy zone. 
The highest technology standards in the world are set in the United States. It's where companies like Google, Meta, and NVIDIA were built – companies that now command multi-trillion-dollar market capitalizations. They didn't get there by retrofitting for scale, compliance, or scrutiny later. They were built for it from day one.
RAD Intel was built the same way. Developed inside real Fortune 1000 workflows, the platform was shaped by U.S. enterprise requirements around performance, governance, and accountability. Today, revenue has grown 2x year over year, and the company's valuation has increased more than 5,000% in roughly four years. Learn more before the share price moves. The zone lines up with market action from 2022 to 2024, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating shares. Abbott Laboratories Growth Accelerates At worst, Abbott's Q4 results and guidance included a few metrics that missed expectations. Still, revenue of $11.46 billion represented a 4.5% year-over-year increase, margins improved, and adjusted earnings accelerated. Revenue growth missed expectations by several hundred basis points, but margin strength helped offset that shortfall: adjusted earnings per share (EPS) rose about 12% and came in slightly ahead of consensus. By segment, results highlighted the resilience of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted — Nutrition declined nearly 9% — but gains in Established Pharmaceuticals and Med Tech more than offset those weaknesses. The pharma segment grew roughly 9%, driven by generics and emerging markets, while Med Tech expanded about 12.3%, with broad-based strength across its subsegments. Margins improved, though they came in short of some analyst forecasts. A shift in product mix toward higher-margin Med Tech, lower COVID-19 sales and operational improvements helped drive the gains. Management expects that improvement to continue, forecasting roughly 10% earnings growth in 2026 — outpacing revenue growth — which should sustain the company's capital-return program. Capital returns are central to the investment case. Abbott is a Dividend King, having raised its dividend annually for more than 50 years, and appears well positioned to continue that streak. After the pullback the stock yields about 2.5%, and the company is paying out less than 50% of consensus earnings, leaving room for share buybacks — an important offset to dilutive share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts flagged the revenue miss, but there were no major rating or price-target changes the morning of the earnings release. The prevailing view is that this is a fundamentally healthy company that can both return capital to shareholders and continue to reinvest for growth. MarketBeat's consensus share-price target implies as much as ~30% upside, potentially pushing the stock to new all-time highs; even low-end targets suggest modest upside from current levels. Key catalysts include an expanding Med Tech portfolio, greater AI integration across operations and products, widening margins and strategic acquisitions. The acquisition of Exact Sciences, for example, broadens Abbott's revenue and profit streams and adds to its product pipeline. The stock's recent decline has been sharp and could extend further. Yet institutions accumulated shares throughout 2025 and are likely to buy more at discounted prices. Early indications show tentative support in the $105–$110 range, but that level is not yet confirmed. Shares could slide to the low end of the target buy zone — potentially near $95 — before a rebound occurs.
| 
